Turn Therapeutics (NASDAQ:TTRX) Shares Down 6.5% – What’s Next?

Turn Therapeutics Inc. (NASDAQ:TTRX) shares dropped 6.5% during mid-day trading on Thursday . The company traded as low as $9.80 and last traded at $9.86. Approximately 64,512 shares traded hands during trading, a decline of 16% from the average session volume of 77,022 shares. The stock had previously closed at $10.54.

Analyst Upgrades and Downgrades

TTRX has been the topic of a number of recent analyst reports. Weiss Ratings raised Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. Wall Street Zen upgraded shares of Turn Therapeutics to a “hold” rating in a report on Saturday, July 18th. LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Turn Therapeutics Stock Performance

The company has a 50-day moving average price of $8.03 and a two-hundred day moving average price of $5.34. The company has a current ratio of 1.19, a quick ratio of 2.23 and a debt-to-equity ratio of 8.83. The stock has a market capitalization of $285.09 million and a P/E ratio of -33.00.

Institutional Investors Weigh In On Turn Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Hodges Capital Management Inc. acquired a new position in Turn Therapeutics in the fourth quarter valued at approximately $39,000. LPL Financial LLC acquired a new stake in shares of Turn Therapeutics during the 4th quarter worth approximately $51,000. Tamar Securities LLC acquired a new stake in shares of Turn Therapeutics during the 4th quarter worth approximately $59,000. Composition Wealth LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter valued at $63,000. Finally, Jane Street Group LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter valued at $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.